PYMX PolyMedix to Present at J.P. Morgan 25th Annual Healthcare Conference
PHILADELPHIA--(Business Wire)--PolyMedix, Inc. (OTC BB: PYMX), an emerging biotech company developing acute care products for infectious diseases and acute cardiovascular disorders based on biomimetics, announced today that Nicholas Landekic, President and Chief Executive Officer, will present an overview and update on the company at the J.P. Morgan Annual Healthcare Conference being held in San Francisco, January 8-11, 2007. PolyMedix's presentation is scheduled for Thursday January 11, 2007, at 2:00 p.m. PST at the Westin St. Francis Hotel.
About PolyMedix, Inc.
PolyMedix develops acute care products for drug resistant bacteria and acute cardiovascular disorders based on biomimetics - novel non-peptide small molecule drugs that mimic the activity of proteins. PolyMedix's compounds are designed with a proprietary computational drug design technology licensed from the University of Pennsylvania, and are based on the work of Drs. William DeGrado, Michael Klein, and Gregory Tew.
PolyMedix has developed novel small molecule antibiotic drug candidates by mimicking the activity of the host defense proteins, one of the oldest and most effective antimicrobial defense systems present in virtually all living creatures. Unlike many antibiotic drugs which act on biochemical targets and to which bacterial resistance readily develops, PolyMedix's antimicrobial compounds have the potential to be rapid acting broad-spectrum antibiotic because they appear to work biophysically by a novel mechanism that targets and disrupts bacterial cell membranes. These new antibiotics compounds are active against Gram-positive, Gram-negative and drug-resistant bacteria, as well as have antifungal and antiviral properties. Laboratory testing has shown their mechanism of action is associated with a low incidence for the development of resistance.
Drug-resistant bacterial infections are one of the most significant problems facing medicine today. PolyMedix plans to file an IND and start human clinical trials with its first antibiotic drug in 2007.
In acute cardiovascular disorders, the Company is developing an anticoagulant antagonist, a small molecule compound which can reverse the activity of both heparin and low molecular weight heparins. Among other indications, this compound will be developed as a replacement for protamine, currently the only agent approved to reverse heparin activity. PolyMedix hopes that its compound will be safer and easier to use than protamine. Clinical trials are anticipated to begin in 2007.
PolyMedix is also developing polymeric antimicrobial compounds for biomaterials applications, which can be used as additives to paints, plastics, and textiles to create self-sterilizing antimicrobial products and surfaces.
For more information, please visit PolyMedix on its website at www.polymedix.com.
News 
Market Data 
Discover 
